Unmatched Cell Line Collections Are Not Optimal for Identification of PARP Inhibitor Response and Drug Synergies

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Poly (ADP-ribose) polymerase (PARP) inhibitors are effective in BRCA1/2-mutated cancers.
• Clinical translation of preclinical PARP inhibitor studies, including combination therapies, is often limited.
• Limitations in preclinical models may hinder accurate prediction of treatment response.

Purpose of the Study:

• To identify suitable cell line models for investigating PARP inhibitor sensitivity and synergy.
• To assess the correlation between BRCA1/2 mutations and PARP inhibitor response in cell line collections.
• To compare the predictive value of cell line collections versus isogenic models for PARP inhibitor therapies.

Main Methods:

• In silico analysis of cell line collections to correlate BRCA1/2 mutations with PARP inhibitor sensitivity.
• Characterization of an isogenic model with Brca1 and Brca2 mutations.
• Evaluation of treatment responses in cell line collections and an isogenic model under monotherapy and combination therapy with platinum-based chemotherapy.

Main Results:

• BRCA1/2-altered cell lines did not show increased sensitivity to PARP inhibitors in cell line collections.
• High PARP1 expression and low-level genomic alterations correlated with PARP inhibitor sensitivity.
• Cell line collections failed to reflect improved patient outcomes with combination PARP inhibitor and platinum therapy.
• An ID8 isogenic model with Brca1/2 mutations mirrored patient tumor responses to PARP inhibitor monotherapy and combination therapy.

Conclusions:

• Caution is advised when selecting cell line collections for PARP inhibitor sensitivity and synergy studies.
• Isogenic preclinical models are more likely to accurately predict patient tumor response to PARP inhibitors.
• Further validation in additional isogenic systems is needed to broaden the scope of these findings.